Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005886 · ClinicalTrials.gov registry record · Phase 1
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase 1 study of Breast Cancer, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Study locations
NCT00005886: Completed Phase 1 study of Breast Cancer, sponsored by University of Kansas Medical Center.
NCT00005886 is a Phase 1 study of Breast Cancer that has completed, run by University of Kansas Medical Center. The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005886, a Phase 1 study of Breast Cancer, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9
- Study locations
Study Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen or LY353381 may fight breast cancer by blocking the use of estrogen. PURPOSE: This randomized phase I trial is studying how well tamoxifen works on the biomarkers of the tumor tissue, compared with LY353381, in treating women with newly diagnosed breast cancer.
Conditions Studied
Interventions
- DRUG tamoxifen citrate
- DRUG arzoxifene hydrochloride
Study Locations (9)
California
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- Comprehensive Cancer Centers of the Desert - Palm Springs
Ohio
- Cleveland Clinic Taussig Cancer Center - Cleveland
- Arthur G. James Cancer Hospital - Ohio State University - Columbus
Alabama
- University of Alabama at Birmingham Comprehensive Cancer Center - Birmingham
Illinois
- Loyola University Medical Center - Maywood
Kansas
- University of Kansas Medical Center - Kansas City
Pennsylvania
- Kimmel Cancer Center of Thomas Jefferson University - Philadelphia - Philadelphia
Texas
- U.S. Oncology Research Inc. - Dallas
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-07 |
| Est. Completion | 2002-08 |
| Phase | Phase 1 |
What the finished NCT00005886 record still lists
NCT00005886 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which tamoxifen citrate is the first listed.
NCT00005886 lists 9 locations in 7 states (California, Ohio, Alabama).
Frequently Asked Questions
What is clinical trial NCT00005886 about?
NCT00005886 is a clinical study titled "Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer". RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen or LY353381 may fight breast cancer by blocking the use of estrogen. PURPOSE: This randomized phase I trial is studying how well tamoxifen works on the biomarkers of the tumor tissue, compared with ...
What is the current status of trial NCT00005886?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-07. Estimated completion is 2002-08.
What conditions does trial NCT00005886 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00005886?
The interventions under investigation include: tamoxifen citrate (DRUG), arzoxifene hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00005886?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005886 being conducted?
This trial has 9 study locations across Alabama, California, Illinois, Kansas, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia